Furosemide interactions with brain GABAA receptors.
1. The loop diuretic furosemide is known to antagonize the function of gamma-aminobutyric acid type A (GABAA) receptors. The purpose of the present study was to examine the direct interaction of furosemide with the GABAA receptors by autoradiography and ligand binding studies with native rat and human receptors and with recombinant receptors composed of rat subunits. 2. Autoradiography with [35S]-t-butylbicyclophosphorothionate ([35S]-TBPS) as a ligand indicated that furosemide (0.1-1 mM) reversed the 5 microM GABA-induced inhibition of binding only in the cerebellar granule cell layer of rat brain sections. In all other regions studied, notably also in the hippocampal and thalamic areas, furosemide failed to antagonize GABA. Furosemide 1 mM decreased [35S]-TBPS binding only in a limited number of brain regions, but facilitation of the GABA-inhibition of the binding was much more widespread. 3. In well-washed rat cerebellar, but not cerebrocortical, membranes, furosemide enhanced the [35S]-TBPS binding over basal level in the absence of added GABA. The GABAA antagonist, SR 95531, and the convulsant, Ro 5-4864, blocked this furosemide-induced increase. Both interactions with the furosemide enhancement are likely to be allosteric, since furosemide affected the binding of [3H]-SR 95531 and [3H]-Ro 5-4864 identically in the cerebellar and cerebrocortical membranes. Maximal GABA-antagonism induced by furosemide in cerebellar membranes was further increased by SR 95531 but not by Ro 5-4864, indicating additive antagonism only for SR 95531. In human cerebellar receptors, only GABA antagonism by furosemide, but not the enhancement without added GABA, was observed. 4. In recombinant GABAA receptors, furosemide antagonism of GABA-inhibition of [35S]-TBPS binding depended only on the presence of alpha 6 and beta 2/3 subunits, irrespective of the presence or absence of gamma 2 or delta subunits. 5. In alpha 6 beta 3 gamma 2 receptors, clozapine reversed the enhancement of [35S]-TBPS binding by furosemide in the absence of GABA. However, it failed to affect the GABA-antagonism of furosemide, suggesting that the enhancement of basal binding and the GABA antagonism might represent two different allosteric actions of furosemide. 6. In conclusion, the present results indicate that furosemide is a subtype-selective GABAA antagonist with a mode of action not shared by several other antagonists, which makes furosemide a unique compound for development of potential GABAA receptor subtype-specific and -selective ligands.
Korpi
E R
ER
Department of Pharmacology and Clinical Pharmacology, University of Turku, Finland.
Lüddens
H
H
D000818:Animals; D001345:Autoradiography; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D002460:Cell Line; D003024:Clozapine / Q000494:pharmacology; D004232:Diuretics / Q000378:metabolism / Q000494:pharmacology*; D005665:Furosemide / Q000378:metabolism / Q000494:pharmacology*; D018756:GABA Antagonists / Q000494:pharmacology; D006801:Humans; D008297:Male; D011724:Pyridazines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D011963:Receptors, GABA-A / Q000187:drug effects / Q000378:metabolism*; D011994:Recombinant Proteins / Q000378:metabolism
D004232:Diuretics; D018756:GABA Antagonists; D011724:Pyridazines; D011963:Receptors, GABA-A; D011994:Recombinant Proteins; D005665:Furosemide; C049853:gabazine; D003024:Clozapine